Global Antibody Development Services Market

Antibody Development Services Comprehensive Study by Type (Antibody Development, Antigen Preparation, Immunization Production, Antibody Characterization, Antibody Production, Antibody Purification, Antibody Labelling Service), End User (Bio Technologies Company, Pharmaceutical Companies, Others), Service (Monoclonal, Polyclonal, Specialised Antibody service) Players and Region - Global Market Outlook to 2027

Antibody Development Services Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Antibody Development ServicesMarket?
Rising global prevalence of infectious and chronic diseases, and rapid advancements in protein therapeutics are some of the key factors driving market growth. Antibodies are biological products that are commonly used in academic and pharmaceutical research. Antibody production is the most visible manifestation of adaptive immune responses, and antibodies are primarily produced to neutralise or eliminate antigens or pathogens. Antibody production has become an essential component of many modern research disciplines, and polyclonal antibody production is an important research activity to broaden its application scope for a variety of disease indications.

Antibody Development Services Market Report Coverage
Report CoverageDetails
Study Timeframe2017 to 2027
Base Year2021
Growth Drivers
  • Rising global prevalence of infectious and chronic diseases
  • Highly reproducing capacity and scalability drives the market growth
Challenges & Pitfalls
  • Lack of skilled labor restrict the market growth


Opportunities
Increased demand for personalized medicine and therapeutic conditions creates lucrative market growth opportunities. and Rapid advancement in protein therapeutic creates tremendous opportunities for the market

Restraints
  • High capital cost associated with the production
  • Time-consuming projects in the antibody development services market limit growth.


The Players Covered in the Study are:
Abcam plc (United Kingdom), Merck KGaA (Germany), Cell Signaling Technology, Inc. (United States), GE Healthcare (United States), Thermo Fisher Scientific Inc. (United States), F. Hoffmann-La Roche AG (Germany), Santa Cruz Biotechnology, Inc. (United States), Becton Dickinson and Company (United States), Rockland Immunochemicals Inc. (United States), Johnson and Johnson (United States), Miltenyi Biotec (Germany), Antibody Solutions (United States), Antibodies Inc. (United States), BioCompare (United States) and Genscript (United States)
Regulatory Framework:
The FDA's regulation on human prescription drugs with fixed-combination sequences (21 CFR 300.50) does not apply to the development of bispecific antibodies, which are single molecules. Although it is not usually requested, the FDA may, in some cases, request a comparison of the bispecific antibody to an approved monospecific product(s) directed against the same antigenic target(s) to inform the benefit-risk assessment of the bispecific antibody.

Available Customization:
A list of players that can be included in the study on an immediate basis are Sinobiological (China), Rndsystems (United States), Bhatbiotech (India) and Abgenex (India).


Market Development Activities
In April 2022, Asahi Kasei acquired CDMO Bionova, expanding its antibody manufacturing capabilities. With the acquisition of Bionova Scientific, a Bay Area biologics manufacturer, Asahi Kasei Medical is expanding into the CDMO business. and In September 2021, PerkinElmer has completed its acquisition of Antibody and Reagent Leader BioLegend. The largest acquisition in PerkinElmer's history broadens the Company's life science franchise into high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation, and bioprocessing.

In March 2022, Sanofi announced an exclusive collaboration agreement with Seagen Inc. to design, develop, and commercialise antibody-drug conjugates (ADCs) for up to three cancer targets. Sanofi's proprietary monoclonal antibody (mAb) technology and Seagen's proprietary ADC technology will be used in the collaboration. Sanofi currently has one ADC in development. ADCs are antibodies that are engineered to deliver potent anti-cancer drugs to tumour cells that express a specific protein. and In January 2022, Boehringer Ingelheim has announced a partnership with MabGenesis to discover and develop novel canine monoclonal antibodies. Using the MabGenesis platform technologies, this collaboration aims to discover novel therapeutic antibodies in dogs. In Boehringer Ingelheim's R&D strategy, strengthening partnerships to accelerate innovation is critical.

Report Objectives / Segmentation Covered

By Type
  • Antibody Development
  • Antigen Preparation
  • Immunization Production
  • Antibody Characterization
  • Antibody Production
  • Antibody Purification
  • Antibody Labelling Service
By End User
  • Bio Technologies Company
  • Pharmaceutical Companies
  • Others

By Service
  • Monoclonal
  • Polyclonal
  • Specialised Antibody service

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising global prevalence of infectious and chronic diseases
      • 3.2.2. Highly reproducing capacity and scalability drives the market growth
    • 3.3. Market Challenges
      • 3.3.1. Lack of skilled labor restrict the market growth
    • 3.4. Market Trends
      • 3.4.1. Increasing government initiative and funding in the sector
      • 3.4.2. Increased R&D activity in the biotechnology and pharmaceutical sectors
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antibody Development Services, by Type, End User , Service and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Antibody Development Services (Value)
      • 5.2.1. Global Antibody Development Services by: Type (Value)
        • 5.2.1.1. Antibody Development
        • 5.2.1.2. Antigen Preparation
        • 5.2.1.3. Immunization Production
        • 5.2.1.4. Antibody Characterization
        • 5.2.1.5. Antibody Production
        • 5.2.1.6. Antibody Purification
        • 5.2.1.7. Antibody Labelling Service
      • 5.2.2. Global Antibody Development Services by: Service (Value)
        • 5.2.2.1. Monoclonal
        • 5.2.2.2. Polyclonal
        • 5.2.2.3. Specialised Antibody service
      • 5.2.3. Global Antibody Development Services Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Australia
          • 5.2.3.2.6. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Antibody Development Services (Price)
      • 5.3.1. Global Antibody Development Services by: Type (Price)
  • 6. Antibody Development Services: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abcam plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck KGaA (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cell Signaling Technology, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GE Healthcare (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Thermo Fisher Scientific Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. F. Hoffmann-La Roche AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Santa Cruz Biotechnology, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Becton Dickinson and Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Rockland Immunochemicals Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson and Johnson (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Miltenyi Biotec (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Antibody Solutions (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Antibodies Inc. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. BioCompare (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Genscript (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Antibody Development Services Sale, by Type, End User , Service and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Antibody Development Services (Value)
      • 7.2.1. Global Antibody Development Services by: Type (Value)
        • 7.2.1.1. Antibody Development
        • 7.2.1.2. Antigen Preparation
        • 7.2.1.3. Immunization Production
        • 7.2.1.4. Antibody Characterization
        • 7.2.1.5. Antibody Production
        • 7.2.1.6. Antibody Purification
        • 7.2.1.7. Antibody Labelling Service
      • 7.2.2. Global Antibody Development Services by: Service (Value)
        • 7.2.2.1. Monoclonal
        • 7.2.2.2. Polyclonal
        • 7.2.2.3. Specialised Antibody service
      • 7.2.3. Global Antibody Development Services Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Australia
          • 7.2.3.2.6. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Antibody Development Services (Price)
      • 7.3.1. Global Antibody Development Services by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antibody Development Services: by Type(USD Million)
  • Table 2. Antibody Development Services Antibody Development , by Region USD Million (2016-2021)
  • Table 3. Antibody Development Services Antigen Preparation , by Region USD Million (2016-2021)
  • Table 4. Antibody Development Services Immunization Production , by Region USD Million (2016-2021)
  • Table 5. Antibody Development Services Antibody Characterization , by Region USD Million (2016-2021)
  • Table 6. Antibody Development Services Antibody Production , by Region USD Million (2016-2021)
  • Table 7. Antibody Development Services Antibody Purification , by Region USD Million (2016-2021)
  • Table 8. Antibody Development Services Antibody Labelling Service , by Region USD Million (2016-2021)
  • Table 9. Antibody Development Services: by Service(USD Million)
  • Table 10. Antibody Development Services Monoclonal , by Region USD Million (2016-2021)
  • Table 11. Antibody Development Services Polyclonal , by Region USD Million (2016-2021)
  • Table 12. Antibody Development Services Specialised Antibody service , by Region USD Million (2016-2021)
  • Table 13. South America Antibody Development Services, by Country USD Million (2016-2021)
  • Table 14. South America Antibody Development Services, by Type USD Million (2016-2021)
  • Table 15. South America Antibody Development Services, by End User USD Million (2016-2021)
  • Table 16. South America Antibody Development Services, by Service USD Million (2016-2021)
  • Table 17. Brazil Antibody Development Services, by Type USD Million (2016-2021)
  • Table 18. Brazil Antibody Development Services, by End User USD Million (2016-2021)
  • Table 19. Brazil Antibody Development Services, by Service USD Million (2016-2021)
  • Table 20. Argentina Antibody Development Services, by Type USD Million (2016-2021)
  • Table 21. Argentina Antibody Development Services, by End User USD Million (2016-2021)
  • Table 22. Argentina Antibody Development Services, by Service USD Million (2016-2021)
  • Table 23. Rest of South America Antibody Development Services, by Type USD Million (2016-2021)
  • Table 24. Rest of South America Antibody Development Services, by End User USD Million (2016-2021)
  • Table 25. Rest of South America Antibody Development Services, by Service USD Million (2016-2021)
  • Table 26. Asia Pacific Antibody Development Services, by Country USD Million (2016-2021)
  • Table 27. Asia Pacific Antibody Development Services, by Type USD Million (2016-2021)
  • Table 28. Asia Pacific Antibody Development Services, by End User USD Million (2016-2021)
  • Table 29. Asia Pacific Antibody Development Services, by Service USD Million (2016-2021)
  • Table 30. China Antibody Development Services, by Type USD Million (2016-2021)
  • Table 31. China Antibody Development Services, by End User USD Million (2016-2021)
  • Table 32. China Antibody Development Services, by Service USD Million (2016-2021)
  • Table 33. Japan Antibody Development Services, by Type USD Million (2016-2021)
  • Table 34. Japan Antibody Development Services, by End User USD Million (2016-2021)
  • Table 35. Japan Antibody Development Services, by Service USD Million (2016-2021)
  • Table 36. India Antibody Development Services, by Type USD Million (2016-2021)
  • Table 37. India Antibody Development Services, by End User USD Million (2016-2021)
  • Table 38. India Antibody Development Services, by Service USD Million (2016-2021)
  • Table 39. South Korea Antibody Development Services, by Type USD Million (2016-2021)
  • Table 40. South Korea Antibody Development Services, by End User USD Million (2016-2021)
  • Table 41. South Korea Antibody Development Services, by Service USD Million (2016-2021)
  • Table 42. Australia Antibody Development Services, by Type USD Million (2016-2021)
  • Table 43. Australia Antibody Development Services, by End User USD Million (2016-2021)
  • Table 44. Australia Antibody Development Services, by Service USD Million (2016-2021)
  • Table 45. Rest of Asia-Pacific Antibody Development Services, by Type USD Million (2016-2021)
  • Table 46. Rest of Asia-Pacific Antibody Development Services, by End User USD Million (2016-2021)
  • Table 47. Rest of Asia-Pacific Antibody Development Services, by Service USD Million (2016-2021)
  • Table 48. Europe Antibody Development Services, by Country USD Million (2016-2021)
  • Table 49. Europe Antibody Development Services, by Type USD Million (2016-2021)
  • Table 50. Europe Antibody Development Services, by End User USD Million (2016-2021)
  • Table 51. Europe Antibody Development Services, by Service USD Million (2016-2021)
  • Table 52. Germany Antibody Development Services, by Type USD Million (2016-2021)
  • Table 53. Germany Antibody Development Services, by End User USD Million (2016-2021)
  • Table 54. Germany Antibody Development Services, by Service USD Million (2016-2021)
  • Table 55. France Antibody Development Services, by Type USD Million (2016-2021)
  • Table 56. France Antibody Development Services, by End User USD Million (2016-2021)
  • Table 57. France Antibody Development Services, by Service USD Million (2016-2021)
  • Table 58. Italy Antibody Development Services, by Type USD Million (2016-2021)
  • Table 59. Italy Antibody Development Services, by End User USD Million (2016-2021)
  • Table 60. Italy Antibody Development Services, by Service USD Million (2016-2021)
  • Table 61. United Kingdom Antibody Development Services, by Type USD Million (2016-2021)
  • Table 62. United Kingdom Antibody Development Services, by End User USD Million (2016-2021)
  • Table 63. United Kingdom Antibody Development Services, by Service USD Million (2016-2021)
  • Table 64. Netherlands Antibody Development Services, by Type USD Million (2016-2021)
  • Table 65. Netherlands Antibody Development Services, by End User USD Million (2016-2021)
  • Table 66. Netherlands Antibody Development Services, by Service USD Million (2016-2021)
  • Table 67. Rest of Europe Antibody Development Services, by Type USD Million (2016-2021)
  • Table 68. Rest of Europe Antibody Development Services, by End User USD Million (2016-2021)
  • Table 69. Rest of Europe Antibody Development Services, by Service USD Million (2016-2021)
  • Table 70. MEA Antibody Development Services, by Country USD Million (2016-2021)
  • Table 71. MEA Antibody Development Services, by Type USD Million (2016-2021)
  • Table 72. MEA Antibody Development Services, by End User USD Million (2016-2021)
  • Table 73. MEA Antibody Development Services, by Service USD Million (2016-2021)
  • Table 74. Middle East Antibody Development Services, by Type USD Million (2016-2021)
  • Table 75. Middle East Antibody Development Services, by End User USD Million (2016-2021)
  • Table 76. Middle East Antibody Development Services, by Service USD Million (2016-2021)
  • Table 77. Africa Antibody Development Services, by Type USD Million (2016-2021)
  • Table 78. Africa Antibody Development Services, by End User USD Million (2016-2021)
  • Table 79. Africa Antibody Development Services, by Service USD Million (2016-2021)
  • Table 80. North America Antibody Development Services, by Country USD Million (2016-2021)
  • Table 81. North America Antibody Development Services, by Type USD Million (2016-2021)
  • Table 82. North America Antibody Development Services, by End User USD Million (2016-2021)
  • Table 83. North America Antibody Development Services, by Service USD Million (2016-2021)
  • Table 84. United States Antibody Development Services, by Type USD Million (2016-2021)
  • Table 85. United States Antibody Development Services, by End User USD Million (2016-2021)
  • Table 86. United States Antibody Development Services, by Service USD Million (2016-2021)
  • Table 87. Canada Antibody Development Services, by Type USD Million (2016-2021)
  • Table 88. Canada Antibody Development Services, by End User USD Million (2016-2021)
  • Table 89. Canada Antibody Development Services, by Service USD Million (2016-2021)
  • Table 90. Mexico Antibody Development Services, by Type USD Million (2016-2021)
  • Table 91. Mexico Antibody Development Services, by End User USD Million (2016-2021)
  • Table 92. Mexico Antibody Development Services, by Service USD Million (2016-2021)
  • Table 93. Antibody Development Services: by Type(USD/Units)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Antibody Development Services: by Type(USD Million)
  • Table 110. Antibody Development Services Antibody Development , by Region USD Million (2022-2027)
  • Table 111. Antibody Development Services Antigen Preparation , by Region USD Million (2022-2027)
  • Table 112. Antibody Development Services Immunization Production , by Region USD Million (2022-2027)
  • Table 113. Antibody Development Services Antibody Characterization , by Region USD Million (2022-2027)
  • Table 114. Antibody Development Services Antibody Production , by Region USD Million (2022-2027)
  • Table 115. Antibody Development Services Antibody Purification , by Region USD Million (2022-2027)
  • Table 116. Antibody Development Services Antibody Labelling Service , by Region USD Million (2022-2027)
  • Table 117. Antibody Development Services: by Service(USD Million)
  • Table 118. Antibody Development Services Monoclonal , by Region USD Million (2022-2027)
  • Table 119. Antibody Development Services Polyclonal , by Region USD Million (2022-2027)
  • Table 120. Antibody Development Services Specialised Antibody service , by Region USD Million (2022-2027)
  • Table 121. South America Antibody Development Services, by Country USD Million (2022-2027)
  • Table 122. South America Antibody Development Services, by Type USD Million (2022-2027)
  • Table 123. South America Antibody Development Services, by End User USD Million (2022-2027)
  • Table 124. South America Antibody Development Services, by Service USD Million (2022-2027)
  • Table 125. Brazil Antibody Development Services, by Type USD Million (2022-2027)
  • Table 126. Brazil Antibody Development Services, by End User USD Million (2022-2027)
  • Table 127. Brazil Antibody Development Services, by Service USD Million (2022-2027)
  • Table 128. Argentina Antibody Development Services, by Type USD Million (2022-2027)
  • Table 129. Argentina Antibody Development Services, by End User USD Million (2022-2027)
  • Table 130. Argentina Antibody Development Services, by Service USD Million (2022-2027)
  • Table 131. Rest of South America Antibody Development Services, by Type USD Million (2022-2027)
  • Table 132. Rest of South America Antibody Development Services, by End User USD Million (2022-2027)
  • Table 133. Rest of South America Antibody Development Services, by Service USD Million (2022-2027)
  • Table 134. Asia Pacific Antibody Development Services, by Country USD Million (2022-2027)
  • Table 135. Asia Pacific Antibody Development Services, by Type USD Million (2022-2027)
  • Table 136. Asia Pacific Antibody Development Services, by End User USD Million (2022-2027)
  • Table 137. Asia Pacific Antibody Development Services, by Service USD Million (2022-2027)
  • Table 138. China Antibody Development Services, by Type USD Million (2022-2027)
  • Table 139. China Antibody Development Services, by End User USD Million (2022-2027)
  • Table 140. China Antibody Development Services, by Service USD Million (2022-2027)
  • Table 141. Japan Antibody Development Services, by Type USD Million (2022-2027)
  • Table 142. Japan Antibody Development Services, by End User USD Million (2022-2027)
  • Table 143. Japan Antibody Development Services, by Service USD Million (2022-2027)
  • Table 144. India Antibody Development Services, by Type USD Million (2022-2027)
  • Table 145. India Antibody Development Services, by End User USD Million (2022-2027)
  • Table 146. India Antibody Development Services, by Service USD Million (2022-2027)
  • Table 147. South Korea Antibody Development Services, by Type USD Million (2022-2027)
  • Table 148. South Korea Antibody Development Services, by End User USD Million (2022-2027)
  • Table 149. South Korea Antibody Development Services, by Service USD Million (2022-2027)
  • Table 150. Australia Antibody Development Services, by Type USD Million (2022-2027)
  • Table 151. Australia Antibody Development Services, by End User USD Million (2022-2027)
  • Table 152. Australia Antibody Development Services, by Service USD Million (2022-2027)
  • Table 153. Rest of Asia-Pacific Antibody Development Services, by Type USD Million (2022-2027)
  • Table 154. Rest of Asia-Pacific Antibody Development Services, by End User USD Million (2022-2027)
  • Table 155. Rest of Asia-Pacific Antibody Development Services, by Service USD Million (2022-2027)
  • Table 156. Europe Antibody Development Services, by Country USD Million (2022-2027)
  • Table 157. Europe Antibody Development Services, by Type USD Million (2022-2027)
  • Table 158. Europe Antibody Development Services, by End User USD Million (2022-2027)
  • Table 159. Europe Antibody Development Services, by Service USD Million (2022-2027)
  • Table 160. Germany Antibody Development Services, by Type USD Million (2022-2027)
  • Table 161. Germany Antibody Development Services, by End User USD Million (2022-2027)
  • Table 162. Germany Antibody Development Services, by Service USD Million (2022-2027)
  • Table 163. France Antibody Development Services, by Type USD Million (2022-2027)
  • Table 164. France Antibody Development Services, by End User USD Million (2022-2027)
  • Table 165. France Antibody Development Services, by Service USD Million (2022-2027)
  • Table 166. Italy Antibody Development Services, by Type USD Million (2022-2027)
  • Table 167. Italy Antibody Development Services, by End User USD Million (2022-2027)
  • Table 168. Italy Antibody Development Services, by Service USD Million (2022-2027)
  • Table 169. United Kingdom Antibody Development Services, by Type USD Million (2022-2027)
  • Table 170. United Kingdom Antibody Development Services, by End User USD Million (2022-2027)
  • Table 171. United Kingdom Antibody Development Services, by Service USD Million (2022-2027)
  • Table 172. Netherlands Antibody Development Services, by Type USD Million (2022-2027)
  • Table 173. Netherlands Antibody Development Services, by End User USD Million (2022-2027)
  • Table 174. Netherlands Antibody Development Services, by Service USD Million (2022-2027)
  • Table 175. Rest of Europe Antibody Development Services, by Type USD Million (2022-2027)
  • Table 176. Rest of Europe Antibody Development Services, by End User USD Million (2022-2027)
  • Table 177. Rest of Europe Antibody Development Services, by Service USD Million (2022-2027)
  • Table 178. MEA Antibody Development Services, by Country USD Million (2022-2027)
  • Table 179. MEA Antibody Development Services, by Type USD Million (2022-2027)
  • Table 180. MEA Antibody Development Services, by End User USD Million (2022-2027)
  • Table 181. MEA Antibody Development Services, by Service USD Million (2022-2027)
  • Table 182. Middle East Antibody Development Services, by Type USD Million (2022-2027)
  • Table 183. Middle East Antibody Development Services, by End User USD Million (2022-2027)
  • Table 184. Middle East Antibody Development Services, by Service USD Million (2022-2027)
  • Table 185. Africa Antibody Development Services, by Type USD Million (2022-2027)
  • Table 186. Africa Antibody Development Services, by End User USD Million (2022-2027)
  • Table 187. Africa Antibody Development Services, by Service USD Million (2022-2027)
  • Table 188. North America Antibody Development Services, by Country USD Million (2022-2027)
  • Table 189. North America Antibody Development Services, by Type USD Million (2022-2027)
  • Table 190. North America Antibody Development Services, by End User USD Million (2022-2027)
  • Table 191. North America Antibody Development Services, by Service USD Million (2022-2027)
  • Table 192. United States Antibody Development Services, by Type USD Million (2022-2027)
  • Table 193. United States Antibody Development Services, by End User USD Million (2022-2027)
  • Table 194. United States Antibody Development Services, by Service USD Million (2022-2027)
  • Table 195. Canada Antibody Development Services, by Type USD Million (2022-2027)
  • Table 196. Canada Antibody Development Services, by End User USD Million (2022-2027)
  • Table 197. Canada Antibody Development Services, by Service USD Million (2022-2027)
  • Table 198. Mexico Antibody Development Services, by Type USD Million (2022-2027)
  • Table 199. Mexico Antibody Development Services, by End User USD Million (2022-2027)
  • Table 200. Mexico Antibody Development Services, by Service USD Million (2022-2027)
  • Table 201. Antibody Development Services: by Type(USD/Units)
  • Table 202. Research Programs/Design for This Report
  • Table 203. Key Data Information from Secondary Sources
  • Table 204. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antibody Development Services: by Type USD Million (2016-2021)
  • Figure 5. Global Antibody Development Services: by Service USD Million (2016-2021)
  • Figure 6. South America Antibody Development Services Share (%), by Country
  • Figure 7. Asia Pacific Antibody Development Services Share (%), by Country
  • Figure 8. Europe Antibody Development Services Share (%), by Country
  • Figure 9. MEA Antibody Development Services Share (%), by Country
  • Figure 10. North America Antibody Development Services Share (%), by Country
  • Figure 11. Global Antibody Development Services: by Type USD/Units (2016-2021)
  • Figure 12. Global Antibody Development Services share by Players 2021 (%)
  • Figure 13. Global Antibody Development Services share by Players (Top 3) 2021(%)
  • Figure 14. Global Antibody Development Services share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Abcam plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. Abcam plc (United Kingdom) Revenue: by Geography 2021
  • Figure 18. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Merck KGaA (Germany) Revenue: by Geography 2021
  • Figure 20. Cell Signaling Technology, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Cell Signaling Technology, Inc. (United States) Revenue: by Geography 2021
  • Figure 22. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 23. GE Healthcare (United States) Revenue: by Geography 2021
  • Figure 24. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2021
  • Figure 26. F. Hoffmann-La Roche AG (Germany) Revenue, Net Income and Gross profit
  • Figure 27. F. Hoffmann-La Roche AG (Germany) Revenue: by Geography 2021
  • Figure 28. Santa Cruz Biotechnology, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Santa Cruz Biotechnology, Inc. (United States) Revenue: by Geography 2021
  • Figure 30. Becton Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 31. Becton Dickinson and Company (United States) Revenue: by Geography 2021
  • Figure 32. Rockland Immunochemicals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Rockland Immunochemicals Inc. (United States) Revenue: by Geography 2021
  • Figure 34. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 35. Johnson and Johnson (United States) Revenue: by Geography 2021
  • Figure 36. Miltenyi Biotec (Germany) Revenue, Net Income and Gross profit
  • Figure 37. Miltenyi Biotec (Germany) Revenue: by Geography 2021
  • Figure 38. Antibody Solutions (United States) Revenue, Net Income and Gross profit
  • Figure 39. Antibody Solutions (United States) Revenue: by Geography 2021
  • Figure 40. Antibodies Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. Antibodies Inc. (United States) Revenue: by Geography 2021
  • Figure 42. BioCompare (United States) Revenue, Net Income and Gross profit
  • Figure 43. BioCompare (United States) Revenue: by Geography 2021
  • Figure 44. Genscript (United States) Revenue, Net Income and Gross profit
  • Figure 45. Genscript (United States) Revenue: by Geography 2021
  • Figure 46. Global Antibody Development Services: by Type USD Million (2022-2027)
  • Figure 47. Global Antibody Development Services: by Service USD Million (2022-2027)
  • Figure 48. South America Antibody Development Services Share (%), by Country
  • Figure 49. Asia Pacific Antibody Development Services Share (%), by Country
  • Figure 50. Europe Antibody Development Services Share (%), by Country
  • Figure 51. MEA Antibody Development Services Share (%), by Country
  • Figure 52. North America Antibody Development Services Share (%), by Country
  • Figure 53. Global Antibody Development Services: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Abcam plc (United Kingdom)
  • Merck KGaA (Germany)
  • Cell Signaling Technology, Inc. (United States)
  • GE Healthcare (United States)
  • Thermo Fisher Scientific Inc. (United States)
  • F. Hoffmann-La Roche AG (Germany)
  • Santa Cruz Biotechnology, Inc. (United States)
  • Becton Dickinson and Company (United States)
  • Rockland Immunochemicals Inc. (United States)
  • Johnson and Johnson (United States)
  • Miltenyi Biotec (Germany)
  • Antibody Solutions (United States)
  • Antibodies Inc. (United States)
  • BioCompare (United States)
  • Genscript (United States)
Additional players considered in the study are as follows:
Sinobiological (China) , Rndsystems (United States) , Bhatbiotech (India) , Abgenex (India)
Select User Access Type

Key Highlights of Report


Aug 2022 217 Pages 61 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Antibody Development Services Market Quantitative research analysis
Global Antibody Development Services Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Antibody Development Services market are Abcam plc (United Kingdom), Merck KGaA (Germany), Cell Signaling Technology, Inc. (United States), GE Healthcare (United States), Thermo Fisher Scientific Inc. (United States), F. Hoffmann-La Roche AG (Germany), Santa Cruz Biotechnology, Inc. (United States), Becton Dickinson and Company (United States), Rockland Immunochemicals Inc. (United States), Johnson and Johnson (United States), Miltenyi Biotec (Germany), Antibody Solutions (United States), Antibodies Inc. (United States), BioCompare (United States) and Genscript (United States), to name a few.
"Increasing government initiative and funding in the sector " is seen as one of major influencing trends for Antibody Development Services Market during projected period 2021-2027.
is dominating the Antibody Development Services Market.
The Antibody Development Services market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Antibody Development Services Market Report?

Have a Query? Click Here

Other Related Reports

Sex Hormones- Comprehensive Study by Type (Progesterone, Testosterone, Drospirenone), Application (Topical, Inhalation, Injection, Others) Players and Region - Global Market Outlook to 2027
$ 3800
Machine Learning in Healthcare- Comprehensive Study by Type (Software Solutions, Hardware, Services), Application (Robot-Assisted Surgery, Virtual Assistants, Administrative Workflow Assistants, Conn...
$ 3800
Electroanatomical Cardiac Mapping Comprehensive Study by Type (Contact Cardiac, Non-Contact Cardiac), Indication (Atrial Fibrillation, Atrial Flutter, AVNRT, Other) Players and Region - Global Market...
$ 3800
Intelligent Hospital System - Comprehensive Study by Type (Appointment Management, Patient Management, Facility Management, Staff Management, Supply Management, Others), Application (Hospitals, Clini...
$ 3800
Next Generation Sequencing (NGS) Product Comprehensive Study by Type (NGS Consumables, Presequencing Products & Services, NGS Platforms, Bioinformatics, Others), Application (Oncology, Reproductive H...
$ 3800
Cardiac Marker Analyzers Comprehensive Study by Application (Hospital, Clinic), Types of Cardiac Markers (Troponin, Creatine kinase (CK), Myoblobin, Lactate dehydrogenase (LDH), C-reactive protein (C...
$ 3600